Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.
martes, 13 de febrero de 2018
Ensuring a stable, secure supply of a critical radioactive imaging product | Advancing next-gen antibiotics | New events
FDA and NRC pave way for first domestic supply of the most commonly used medical isotope in diagnostic imaging
System will help save and improve lives of patients, reduce risk of drug shortages, and strengthen national security
FDA and the Nuclear Regulatory Commission (NRC) took steps to ensure a stable and secure supply of a critical radioactive imaging product used to detect potentially life-threatening diseases. On February 8, 2018, FDA approved the RadioGenix System, a unique system for producing Technetium-99m (Tc-99m), the most widely used radioisotope in medical imaging.
From FDA Commissioner Scott Gottlieb, M.D:
"This new technology was the result of a broad collaboration across the federal government and industry, and has the potential to benefit many patients as well as restore the U.S. ability to domestically supply a critical medical diagnostic tool for the first time in 30 years.
The system we’ve approved today will not only help save and improve the lives of patients, but will reduce the risk of drug shortages and strengthen our national security by creating a U.S.-based manufacturing capacity that is less vulnerable to supply disruptions." Read the full statement
Image: Reactor pool at the High Flux Isotope Reactor (HFIR) at Oak Ridge National Laboratory. Primarily a research reactor, the HFIR is also used for production of medical isotopes. Credit: U.S. Department of Energy Flickr
FDA reports on progress advancing policies for developing next-generation antibiotics
HHS released a report to Congress on progress made in facilitating the development and approval of new antibacterial and antifungal drugs, implementing stewardship programs to ensure their judicious use and assessing the impact of the Generating Antibiotic Incentives Now (GAIN) provisions on promoting the pipeline of antibacterial and antifungal drugs.
New! March 8, 2018: FDA Grand Rounds webcast - Are Stem Cells Ready for Prime Time? A Look at FDA Research Advances in Regenerative Medicine, 12:00 - 1:00 p.m. ET, presented by Steven Bauer, PhD, Chief, Cellular and Tissue Therapy, Division of Cellular and Gene Therapies, CBER
April 17-20, 2018: Preparedness Summit (Atlanta, GA) - The theme for the conference is Strengthening National Health Security: Mastering Ordinary Responses, Building Resilience for Extraordinary Events. Registration is now open. (fee)
FDA launched a new set of web pages that aims to provide a one-stop source for general information about Risk Evaluation and Mitigation Strategy (REMS) programs (January 29, 2018)
FDA published updates to the Payment for Research Subjects: Information Sheet to clarify that reimbursement for travel expenses to and from the clinical trial site and associated costs such as airfare, parking, and lodging are acceptable under current practices. (January 29, 2018)
From FEMA - The FEMA Youth Preparedness Council is accepting applications for young leaders in grades 8-11 who are interested and engaged in advocating youth preparedness and making a difference in their communities. Applications are due March 18, 2018.
From DARPA - Reading the Body’s History of Threat Exposure - DARPA's new Epigenetic CHaracterization and Observation (ECHO) program aims to build a field-deployable platform technology that quickly reads someone’s epigenome and identifies signatures that indicate whether that person has ever—in his or her lifetime—been exposed to materials that could be associated with weapons of mass destruction (WMD). DARPA will host a Proposer's Day on February 23, 2018in Arlington, VA.
ver historia personal en: www.cerasale.com.ar [dado de baja por la Cancillería Argentina por temas políticos, propio de la censura que rige en nuestro medio]//
weblog.maimonides.edu/farmacia/archives/UM_Informe_Autoevaluacion_FyB.pdf - //
weblog.maimonides.edu/farmacia/archives/0216_Admin_FarmEcon.pdf - //
www.proz.com/kudoz/english_to_spanish/art_literary/523942-key_factors.html - 65k - // www.llave.connmed.com.ar/portalnoticias_vernoticia.php?codigonoticia=17715 // www.frusculleda.com.ar/homepage/espanol/activities_teaching.htm // http://www.on24.com.ar/nota.aspx?idNot=36331 ||